Montgomery et al. reported that a significant and sustained post-operative elevations of CA 19-9 serum levels preceded clinical or radiologic detection of recurrence by 2 weeks to 5 months (median 3.5 months) and that an elevated post-operative CA 19-9 serum levels >180 U/mL was associated with a disease free survival of 12 months compared to 35 months for patients with post-operative CA 19-9 serum levels <180 U/mL (50). In this study, patients whose postoperative CA 19-9 values normalized by 3 to 6 months (<37 U/mL) had a longer disease free
survival (24 vs. 10 months, P<0.04) and median survival (34 vs. 13 months, Inhibitors,research,lifescience,medical P<0.04). Hernandez et al. analyzed data from 96 surgically resected pancreatic cancer patients in whom CA 19-9 serum Inhibitors,research,lifescience,medical levels were drawn at baseline, 4 weeks, and 12-week intervals following surgery and for whom CA 19-9 velocity was calculated (rate of change in CA 19-9 levels over a 4-week period). These authors found that CA 19-9 velocity was a better predictor of
overall survival than baseline CA 19-9 serum levels (P<0.001). Patients with disease progression had a CA 19-9 velocity of 131 U/mL/4-weeks compared to a velocity of 1 U/ml/4-weeks at 22 months for Inhibitors,research,lifescience,medical patients without disease progression (P<0.001) (51). In summary, the above results imply that clinical or radiologic post-operative recurrence is often preceded or associated with elevated CA 19-9 serum levels by 2-6 months. Elevation of post-operative CA 19-9 serum levels or failure of the CA 19-9 serum levels to normalize in the post-operative period suggest the presence of residual tumor or remnant disease and is associated with a poor prognosis. Limitations that undermine the utility
Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical of CA 19-9 serum level as a preferred tumor marker for pancreatic cancer. Despite multiple clinical applications for CA 19-9 serum levels in pancreatic cancer patients, the diagnostic utility of CA 19-9 is limited due to a low or modest sensitivity (79-81%) in symptomatic patients and a low PPV (0.9%) which makes it suboptimal screening test (12,14,16,18,19). Even among individuals at higher risk of pancreatic cancer (hereditary pancreatitis, family history of pancreatic cancer, Peutz-Jeghers syndrome), CA 19-9 serum levels fail to identify early/small tumors Anacetrapib or precancerous lesions in 10-15% of patients (68), is elevated in only 80-85% of pancreatic cancer patients (12,14,20). The CA 19-9 serum levels are not predictive of tumor location or differentiation. As noted earlier, CA 19-9 serum levels may be elevated in a variety of non-pancreatic neoplastic conditions resulting in a high false positive rate (10-30%). Benign conditions associated with elevated serum CA 19-9 levels selleck screening library include ovarian cyst, heart failure, hashimoto’s thyroiditis, rheumatoid arthritis and www.selleckchem.com/products/Bortezomib.html diverticulitis (16-19,69-74) (Table 6).